RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Neuro, Any thoughts on the delay of Schering's Saphris/Asenapine approval? Even if approved, do you think it will be competitive in the marketplace?

From Cortex's perspective, I guess the FDA's rejection of Schering/Organon's Suggamedex last year was potentially a key development, since its approval could have put Schering in the mix as a potential RD partner.

Speaking of Schering, they'll soon have their Org-26576 ADHD Phase 2 results (the 'final data collection date' is Jan '09, and 'study completion date' is March '09). They should already have the Org-26576 Depression Phase 1/2 data.